PMON329 Survey of physician experience with once weekly somatrogon vs once daily somatropin regimen for the treatment of pediatric patients with growth hormone deficiency: results from a cross sectional, observational study

BACKGROUND: Somatrogon is a long-acting recombinant human growth hormone (hGH) currently being developed as a once-weekly subcutaneous injectable treatment for pediatric patients with growth hormone deficiency (GHD). A recent global Phase 3 study compared the efficacy and safety of somatrogon admini...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez, Roy, Loftus, Jane, Yaworsky, Andrew, Lamoureux, Roger, Polak, Michel, Maghnie, Mohamad, Miller, Bradley S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625705/
http://dx.doi.org/10.1210/jendso/bvac150.1303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625705/
http://dx.doi.org/10.1210/jendso/bvac150.1303

Ejemplares similares